Evidence of the involvement of K+ channels and PPARγ receptors in the antidepressant-like activity of diphenyl diselenide in mice

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 9, 2010, Pages 1121-1127

  Wilhelm, Ethel A ^a   Jesse, Cristiano R ^a   Bortolatto, Cristiani F ^a   Barbosa, Nilda B V ^a   Nogueira, Cristina W ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

Author keywords

antidepressant; peroxisome proliferator activated receptor gamma; potassium channels; selenium

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; APAMIN; CHARYBDOTOXIN; CROMAKALIM; DIPHENYL DISELENIDE; GLIBENCLAMIDE; MINOXIDIL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POTASSIUM CHANNEL; TETRYLAMMONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; IMMOBILIZATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPEN FIELD TEST; PROTEIN PROTEIN INTERACTION;

ANILIDES; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZENE DERIVATIVES; CROMAKALIM; DEPRESSION; HINDLIMB SUSPENSION; MALE; MICE; MINOXIDIL; ORGANOSELENIUM COMPOUNDS; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; PPAR GAMMA; VASODILATOR AGENTS;

EID: 77955237635     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01132.x     Document Type: Article

References (53)

1. Hankin BL. Adolescent depression: description, causes, and interventions. Epilepsy Behav 2006 8 : 102 104.
2. Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006 7 : 137 151.
3. Meotti FC et al. Protective role of aryl and alkyl diselenides on lipid peroxidation. Environ Res 2004 94 : 276 282.
4. Borges LP et al. Protective effect of diphenyl diselenide on acute liver damage induced by 2-nitropropane in rats. Toxicology 2005 210 : 1 8.
5. Da Rocha JT et al. Hypolipidaemic activity of orally administered diphenyl diselenide in Triton WR-1339-induced hyperlipidaemia in mice. J Pharm Pharmacol 2009 61 : 1673 1679.
6. Ineu RP et al. Diphenyl diselenide reverses gastric lesions in rats: involvement of oxidative stress. Food Chem Toxicol 2008 46 : 3023 3029.
7. Savegnago L et al. Monoaminergic agents modulate antidepressant-like effect caused by diphenyl diselenide in rats. Prog Neuropsychopharmacol Biol Psychiatry 2007 31 : 1261 1269.
8. + ATPase activity. Neurosci Lett 2009 455 : 168 172.
9. Burk RF. Selenium, an antioxidant nutrient. Nutr Clin Care 2002 5 : 75 79.
10. Sher L. Depression and suicidal behavior in alcohol abusing adolescents: possible role of selenium deficiency. Minerva Pediatr 2008 60 : 201 209.
11. Rayman MP. The importance of selenium to human health. Lancet 2000 356 : 233 241.
12. Savegnago L et al. Diphenyl diselenide exerts antidepressant-like and anxiolytic-like effects in mice: involvement of 1-arginine-nitric oxide-soluble guanylate cyclase pathway in its antidepressent-like action. Pharmacol Biochem Behav 2008 88 : 418 426.
13. Shin JH et al. Nitric oxide directly activates calcium-activated potassium channels from rat brain reconstituted into planar lipid bilayer. FEBS Lett 1997 415 : 299 302.
14. + channels (rSlo). Mol Cells 2001 12 : 97 102.
15. Galeotti N et al. Effect of potassium channel modulators in mouse forced swimming test. Br J Pharmacol 1999 126 : 1653 1659.
16. Inan SY et al. Dual effects of nitric oxide in the mouse forced swimming test: possible contribution of nitric oxide-mediated serotonin release and potassium channel modulation. Pharmacol Biochem Behav 2004 77 : 457 464.
17. Kaster MP et al. Effects of potassium channel inhibitors in the forced swimming test: possible involvement of L arginine-nitric oxide-soluble guanylate cyclase pathway. Behav Brain Res 2005 165 : 204 209.
18. Choi JS et al. Fluoxetine inhibits A-type potassium currents in primary cultured rat hippocampal neurons. Brain Res 2004 1018 : 201 207.
19. 3H]5-hydroxytryptamine in rat hippocampal slices. J Pharm Exp Therap 1997 282 : 262 270.
20. B receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed rats'. J Neurophysiol 2007 98 : 1 2.
21. + channels by antidepressant drugs. Eur J Pharmacol 2002 452 : 35 48.
22. + channels by various antidepressant drugs. Neuropsychopharmacology 2004 29 : 1841 1851.
23. + channels by the antidepressant paroxetine. J Pharmacol Sci 2006 102 : 278 287. (Pubitemid 44790689)
24. Guo WY et al. The additive effects of quinine on antidepressant drugs in the forced swimming test in mice. Psychopharmacology 1995 121 : 173 179.
25. Guo W et al. Additive effects of glyburide and antidepressants in the forced swimming test: evidence for the involvement of potassium channel blockade. Pharmacol Biochem Behav 1996 54 : 725 730.
26. Heurteaux C et al. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 2006 9 : 1134 1141.
27. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrinol Rev 1999 20 : 649 688.
28. Cimini A et al. Expression of peroxisome proliferator-activated receptors (PPARs) and retinoic acid receptors (RXRs) in rat cortical neurons. Neuroscience 2005 130 : 325 337.
29. Moreno S et al. Immunolocalization of peroxisome proliferator activated receptors and retinoic × receptors in the adult rat CNS. Neuroscience 2004 123 : 131 145.
30. Rosa AO et al. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog Neuropsychopharmacol Biol Psychiatric 2008 32 : 1549 1556.
31. Ahmed AA et al. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav Pharmacol 2009 20 : 635 642.
32. Cryan JF et al. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 2005 29 : 571 625.
33. Varty GB et al. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 2003 14 : 87 95.
34. Chermat R et al. Adaptation of the tail suspension test to the rat. J Pharmacol 1986 17 : 348 350. (Pubitemid 17175387)
35. Thierry B et al. The tail suspension test: ethical considerations. Psychopharmacology 1986 90 : 284 285.
36. Steru L et al. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985 85 : 367 370.
37. Rodrigues ALS et al. Involvement of monoaminergic system in the antidepressant-like effect of the hydroalcoholic extract of Siphocampylus verticillatus. Life Sci 2002 70 : 1347 1358.
38. Mantovani M et al. Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci Lett 2003 34 : 1 4.
39. Walsh RN, Cummins RA. The open-field test: a critical review. Psychol Bull 1976 83 : 482 504.
40. Zomkowski AD et al. Putrescine produces antidepressant-like effects in the forced swimming test and in the tail suspension test in mice. Prog Neuropsychopharmacol Biol Psychiatry 2006 30 : 1419 1425.
41. Paulmier C. Selenoorganic functional groups. In : Paulmier C, ed. Selenium reagents and intermediates in organic synthesis. 1st edn. Oxford : Pergamon Press 1986 : 25 51.
42. Porsolt RD et al. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977 266 : 730 732.
43. Cryan JF et al. Assessing antidepressant activity in rodents: recent developments and future need. TIPS 2002 23 : 238 245.
44. Rodrigues ALS et al. Antidepressant-like and antinociceptive-like actions of 4-(4′-chlorophenyl)-6-(4′′-methylphenyl)-2- hydrazinepyrimidine Mannich base in mice. Pharmacol Biochem Behav 2005 82 : 156 162.
45. Collino M et al. Modulation of the oxidative stress and inflammatory response by PPAR-g agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur J Pharmacol 2006 530 : 70 80.
46. Dehmer T et al. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem 2004 88 : 494 501.
47. Racke M et al. Nuclear receptors and autoimmune disease: the potential of PPAR agonists to treat multiple sclerosis. J Nutr 2006 136 : 700 703.
48. Schein PS. 1-methyl-1-nitrosourea depression of brain nicotinamide adenine dinucleotide in the production of neurologic toxicity. Proc Soc Exp Biol Med 1969 31 : 517 520.
49. Prigol M et al. Convulsant effect of diphenyl diselenide in rats and mice and its relationship to plasma levels. Toxicol Lett 2009 189 : 35 39.
50. Yaffe K et al. PPARgamma pro12Ala genotype and risk of cognitive decline in elders. Neurobiol Aging 2008 29 : 78 83.
51. West NA et al. The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study. Neurobiol Aging 2010 31 : 741 746.
52. Koh WP et al. Peroxisome proliferatoractivated receptor (PPAR)gamma gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis 2006 27 : 1797 1802.
53. Ji-Rong Y et al. Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/centenarians. Arch Med Res 2009 40 : 411 415.